Physician profile
Amy E Karman
NPI 1316398829
$387.06
in general payments reported to CMS, 2019-2025
16 companies · $16.87 in 2025
The $16.87 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5.04 · 2023: $216 · 2024: $149 · 2025: $16.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $382.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $68.89 | 2023-2024 | Enhertu, Injectafer |
| Regeneron Healthcare Solutions, INC. | $45.50 | 2024 | Libtayo |
| Mirati Therapeutics, INC. | $43.32 | 2024 | Krazati |
| Genentech USA, INC. | $24.70 | 2021-2024 | Polivy, Lunsumio, Columvi |
| Eisai INC. | $19.94 | 2023 | |
| Amgen INC. | $19.79 | 2023 | Lumakras |
| Astellas Pharma US INC | $18.95 | 2023 | Xospata |
| Pharmacosmos Therapeutics INC. | $17.77 | 2023 | Monoferric |
| Seagen INC. | $17.00 | 2023 | Padcev |
| Abbvie INC. | $16.87 | 2025 | |
| Alexion Pharmaceuticals, INC. | $16.42 | 2023 | Ultomiris |
| Puma Biotechnology, INC. | $15.99 | 2023 | |
| Lilly USA, LLC | $15.83 | 2024 | Jaypirca, Verzenio, Retevmo |
| Genmab U.S., INC. | $15.45 | 2023 | Epkinly |
| Agios Pharmaceuticals, INC. | $15.42 | 2023 | Pyrukynd |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $15.22 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Karman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.